Excitatory dicarboxylic amino acid and pyramidal neurone neurotransmission of the cerebral cortex in Alzheimer’s disease
Drug development for Alzheimer’s disease has so far had little success, possibly due to failure to correct abnormalities of neurones other than the corticopetal. Most enquiries indicate that cortical inhibitory neurotransmitters are neither selectively nor critically affected. It is highly probable that shrinkage or loss of corticocortical association fibres occurs. This change appears to be circumscribed, clinically relevant and to involve neurotransmitter glutamate. Modulatory domains of the N-methyl-D-aspartate receptor complex are identified as sites at which potential therapeutic agents might be safely directed.
KeywordsPyramidal Neurone Gaba Content Cortical Pyramidal Neurone Glutamic Acid Decarboxylase Activity Primary Agonist
Unable to display preview. Download preview PDF.
- Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Palmer AM, Sims NR, Smith CCT, Spillane JA, Esiri MM, Snowden JS, Wilcock GK, Davison AN (1983) Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer’s disease. J Neurochem 41: 266–272PubMedCrossRefGoogle Scholar
- Corsellis JAN (1962) Mental illness and the ageing brain, Maudsley Monograph 9. Oxford University Press, LondonGoogle Scholar
- Corsellis JAN (1979) Alzheimer’s disease: early recognition of potentially reversible deficits. In: Glen AIM, Whalley LD (eds) Alzheimer’s disease. Early recognition of potentially reversible deficits. Churchill Livingstone, Edinburgh, pp 6Google Scholar
- Lowe SL, Bowen DM (1990) Glutamic acid concentration in brains of patients with Alzheimer’s disease. Biochem Soc Trans (in press)Google Scholar
- Steel JE, Palmer AM, Lowe SL, Bowen DM (1989a) The influence of tetrahydro-9-aminoacridine in excitatory amino acid neurotransmission in vivo and in vitro. Br J Pharmacol 96: 353Google Scholar